Abstract Infantile Refsum disease (IRD) is one of the less severe of Zellweger spectrum disorders (ZSDs), a group of peroxisomal biogenesis disorders resulting from a generalized peroxisomal function impairment. Increased plasma levels of very long chain fatty acids (VLCFA) and phytanic acid are biomarkers used in IRD diagnosis. Furthermore, an increased plasma level of phytanic acid is known to be associated with neurologic damage. Treatment of IRD is symptomatic and multidisciplinary.
improvement was observed, and the long-term clinical effect of this approach needs to be evaluated.
Introduction
Infantile Refsum disease (IRD; OMIM#601539) is the less severe form of Zellweger spectrum disorders (ZSDs), which are a continuum of phenotypes with clinical, biochemical and genetic overlap -Zellweger syndrome, neonatal adrenoleukodystrophy and IRD. Presenting neonatally with hypotonia, large fontanels, failure to thrive and cholestatic jaundice, IRD is later recognizable by developmental delay, retinitis pigmentosa, sensorineural deafness, hepatomegaly, growth retardation and milder dysmorphic features (Baumgartner et al. 1998; Poll-The et al. 2004 ). The disease progresses slowly and some patients may survive into adulthood, depending on the level of clinical care (Poll-The et al. 2004; Crane et al. 2005) .
The IRD diagnosis is made by a combination of clinical manifestations with biochemical and molecular testing, as well as macro-and microscopic examinations and immunocytochemistry analysis of peroxisomes (Aubourg and Wanders 2013) . Diagnostic tools rely on the fact that IRD is an autosomal recessive peroxisomal biogenesis disorder (PBD) caused by pathogenic variants in the PEX genes, which encode peroxins that are essential to peroxisomal assembly and the protein import system, resulting in none or a few abnormally formed peroxisomes, whose functions are generally impaired (Aubourg and Wanders 2013) . Since very long chain fatty acids (VLCFA) beta-oxidation is a unique metabolic function of peroxisomes, the identification of an increased level of VLCFA in plasma, fibroblasts and amniotic fluid cells is a biomarker of ZSD (Wanders 2014) . Elevated plasma levels of phytanic and pristanic acids and bile acid precursors (BAP), as well as reduced plasmalogen levels in erythrocytes, are additional biochemical abnormalities that point to a ZSD (Wanders 2014) . A reduced dihydroxyacetone phosphate acyltransferase (DHAP-AT) activity in fibroblasts and amniocytes confirms the postnatal and prenatal diagnosis of ZSD (Wanders et al. 1995) . Finally, identification of pathogenic mutations in a PEX gene (http://www.dbpex.org) is useful for diagnosis, prognosis, and management of a ZSD, but it also enables carrier testing of at-risk relatives and prenatal or preimplantation diagnosis (Ebberink et al. 2011) .
Management of IRD is multidisciplinary and treatment remains symptomatic (Braverman et al. 2013) . Reports of treatment impact in disease progression are limited. However, sporadically reports have showed that changes in diet lead to specific biochemical effects (Robertson et al. 1988; Moser et al. 1999) .
Herein, we describe an IRD patient with mild biochemical phenotype who had a reduction of plasma phytanic acid levels after onset of dietary management. Slight developmental progress was observed and retinopathy did not evolve significantly during follow-up.
Methods
The following peroxisomal biochemical analyses were performed, as previously reported, with minor modifications: plasma and fibroblast VLCFA quantification (Moser et al. 1999) , plasma phytanic and pristanic acid level quantification (Dacremont et al. 1995) , fibroblast DHAP-AT enzymatic activity measurement (Wanders et al. 1995) , erythrocyte plasmalogen level quantification (Bjorkhem et al. 1986 ), plasma BAP measurement (Shimada et al. 2001 ), plasma polyunsaturated fatty acid level measurement (Bailey-Hall et al. 2008 ) and antibody anti-catalase immunofluorescence labelling (Wanders et al. 1989 ). Genomic DNA was extracted from peripheral blood, using Qiagen BioRobot EZ1 apparatus with EZ1 DNA blood 350 ml kit (according to the manufacturer's instructions). PCR products of all PEX1 exons and flanking regions (reference number, NM_000466.2) were analysed by Sanger sequencing using BigDye Terminator v1.1 Cycle Sequencing Kit and 3130xl Genetic Analyzer (Applied Biosystems) (PCR primers and conditions are available upon request).
The nutritional management to reduce phytanic acid intake from the diet consisted in decreasing global fat intake, mainly from ruminant meats, dairy products and high fat content fish. Griffiths Mental Development Scales were used to evaluate psychomotor development.
Results
A 3-year-and 6-month-old girl was referred to the Medical Genetics outpatient clinic due to retinitis pigmentosa, sensorineural hearing loss (SNHL), developmental delay and dysmorphic craniofacial features (Fig. 1a) . She was born from consanguineous healthy parents, who were first cousins, and she had two older twin brothers, who manifested hypotonia and psychomotor developmental delay associated with extreme prematurity. During gestation, nuchal translucency above the 95th percentile for gestational age prompted a fetal karyotype and a fetal echocardiography, which were unremarkable. She was born at 38 weeks, and, in the neonatal period, hypotonia and jaundice were diagnosed. Low-amplitude and high-frequency bilateral vertical nystagmus was first noticed at 3 months of age. At 6 months, bilateral pigment deposits became apparent in the retinal mid-periphery of both ocular fundi. The following months, these pigment deposits assumed round circular shapes instead of the more typical bone spicule form and approached the posterior pole, while the maculas acquired a salt and pepper appearance and eventually pigment scattering (Fig. 1b) . Electroretinography was performed according to ISCEV standards at 4 years of age and demonstrated an extinguished rod response with a diminished maximum combined rod-cone response, compatible with retinitis pigmentosa. Bilateral and symmetric hyperopic astigmatism was also diagnosed and is currently corrected with glasses. Due to intellectual disability, visual acuity could not be reliably tested. Despite the severe and generalized photoreceptor dysfunction, both parents and other caretakers report good functional vision for indoor and outdoor activities, without tripping or collisions that suggested a markedly reduced visual field, and do not report significant limitations in scotopic conditions (nyctalopia), typical of severe retinitis pigmentosa. Both fundoscopic lesions and hyperopia remained stable during the last 3 years of follow-up. Cerebral MRI did not show brain abnormalities at 10 months old. Seizures were not reported. Profound bilateral SNHL at frequencies 2,000-4,000 Hz was confirmed at 2 years and 11 months old, by auditory evoked potentials. However, conditioned play audiometry showed a 40 dB loss at 250-2,000 Hz bilaterally with the use of hearing aids, placed at approximately 3 years old, and an increased social interaction was concomitantly observed. She seated alone at 8 months and started walking at 24 months. At 4 years, developmental evaluation showed a severe developmental delay across all areas (GQ ¼ 31) (Fig. 1c) . Height and weight progressed along the 5th percentile curve, while head circumference was growing along the 25th percentile curve. At 3 years old, electrocardiography was normal and echocardiography showed patent ductus arteriosus with small left-right shunt but good biventricular function.
Diagnosis of ZSD was considered, due to hearing and visual impairment associated with developmental delay and mild dysmorphic features. At 16 months, quantification of plasma levels of VLCFA did not clearly support this diagnosis, since C26:0 and C24:0/C22:0 ratios were within the normal range and the C26:0/C22:0 ratio was slightly increased (Table 1) . However, at 33 years and 11 months old, increased plasma levels of VLCFA in combination with increased phytanic acid and pristanic acid levels supported the hypothesis of a peroxisomal disorder, either a ZSD or a D-bifunctional protein deficiency. The decreased activity of DHAP-AT in fibroblasts was in accordance with the diagnosis of a ZSD. A pathogenic homozygous missense mutation c.2528G>A, p.(Gly843Asp), was detected in the PEX1 gene, establishing a ZSD diagnosis for this patient. Parents are carriers of the same pathogenic variant. Catalase immunofluorescence analysis showed a punctuate fluorescence pattern in control cells, due to the catalase presence within the peroxisome compartment. In this patient, however, the catalase is predominately scattered in the cytosol, and this leads to a diffuse rather than a punctuate fluorescence pattern (Fig. 2) . From this spectrum, considering the clinical phenotype, this patient can be classified as an IRD.
After diagnosis, nutritional advice and follow-up was proposed. In the first nutritional appointment, at four years and two months old, the fat intake recorded was 29% of the total energy intake (1800 kcal/day). The nutritional prescription reduced the total of fat into 15% of the total energy intake. Diet was also supplemented with maltodextrins, in order to prevent catabolism, resulting in a higher total energy intake (1900 kcal/day). At 7, 12, 18 and 25 months after starting the dietary intervention, plasma levels of phytanic acid lowered to normal range. The subsequent nutritional appointments confirmed the excellent compliance with the proposed diet. The successive developmental evaluations revealed slight progress in all evaluated areas (at 6 years, GQ ¼ 34), most significantly in locomotor and autonomy/sociability (Fig. 1c) . However, her performance was significantly conditioned by a short attention span in more structured tasks.
Discussion
We report a 3-year-old child with IRD, in whom a thorough characterization of the clinical phenotype was critical to support the hypothesis of a peroxisomal disorder, in face of first-tier mild biochemical abnormalities. IRD was considered due to developmental delay associated with hearing loss and progressive retinopathy, since facial dysmorphic features were misleading. Although neurological dysfunction observed in the neonatal period resembled a neuromuscular disorder, later in life, our patient's phenotype also resembled Usher type II, congenital defects of glycosylation or mitochondrial respiratory chain defects. Diagnosing IRD may be complicated due to its phenotypic as well as genotypic heterogeneity, leading eventually to an underestimation of its true prevalence. Since the onset and severity of manifestations is variable and numerous clinical differential diagnoses exist, a clinical suspicion of IRDbased on neurologic, developmental and sensory deficitsshould prompt a systematic biochemical investigation of PBD (Baumgartner et al. 1998) , including measurements in plasma, erythrocytes and skin fibroblasts, to show defects in the a-oxidation, b-oxidation and synthesis of ether phospholipids.
The repeated measurement of plasma VLCFA, along with phytanic acid and pristanic acid, proved valuable in the identification of a ZSD in this specific patient, which was subsequently confirmed by analysis of the DHAP-AT activity in fibroblasts. Biochemical diagnosis of IRD may be challenging in patients with normal or mildly increased plasma VLCFA levels Zeharia et al. 2007 ). Indeed, older individuals were shown to have lower plasma ratios of C24:0/C22:0 and C26:0/C22:0 fatty acids when compared with children under one year (Hall et al. 1988) . Since normal VLCFA plasma levels do not exclude the diagnosis of IRD, this clinical case highlights the need of repeated plasma VLCFA measurements or analysis of additional biochemical parameters, including plasma phytanic acid or erythrocyte plasmalogens, to increase the diagnostic rate of IRD patients (Krause et al. 2009 ).
The mild clinical and biochemical phenotype in this patient is likely to be explained by the type of mutation Plasmalogen values in erythrocytes may normalize with age.
", above maximum reference value. #, below minimum reference value. N, between minimum and maximum reference values detected in the PEX1 gene, as well as by peroxisomal mosaicism, which was observed in the patient's fibroblasts. This child is homozygous for the pathogenic missense variant c.2528G>A (p.Gly843Asp) in PEX1, affecting the second ATP-binding domain of the protein and which may enable transcription into mRNA and translation into protein to a certain extent (Crane et al. 2005) . As a consequence, the binding between PEX1 and PEX6 is reduced but not abolished. This interaction is essential for the peroxisomal protein import system (Tamura et al. 2001 ). In addition, this pathogenic variant influences the PEX1 activity in a temperature-sensitive manner, i.e. while at 37 C import of matrix proteins into "ghost" peroxisomes is observed in some cells (peroxisomal mosaicism), at 30 C, peroxisomal import is almost completely recovered, as well as peroxisomal metabolic functions, and at 40 C, no peroxisomal import is observed (Imamura et al. 1998) . Overall, this pathogenic variant retains a residual peroxisomal function which, along with peroxisomal mosaicism, results in less severe biochemical deficiencies, a milder clinical phenotype and prolonged survival (Osumi et al. 2000; Poll-The et al. 2004; Crane et al. 2005) .
This IRD patient was treated with a phytanic acidrestricted diet, since there is increasing evidence on its toxicity, namely, disturbing normal lipid homeostasis (van den Brink and Wanders 2006). Additionally, carbohydrate supplementation was crucial to maintain an adequate energy intake. This led to persistent plasma phytanic acid level normalization after the onset of the dietary regimen. Similar biochemical results were previously reported in few patients with IRD treated with a low phytanic acid diet (Robertson et al. 1988; Pakzad-Vaezi and Maberley 2014) . However, the long-term clinical benefit of this approach remains to be elucidated. Slow developmental progression was concomitantly observed in this patient. Nonetheless, since the prognosis of IRD is variable, the slow disease progression or halting of the disease progression may be due to the natural history of the disease. Since phytanic acid and pristanic acid originate exclusively from exogenous sources, its accumulation in ZSD patients is dependent on diet, as well as age . Theoretically, the measurement of plasma phytanic acid levels may be regarded as a response marker to the low phytanic acid intake diet. Furthermore, accumulation of phytanic acid over time, through dietary intake, is a diagnostic marker of PBD (Aubourg and Wanders 2013) . Nonetheless, since intermittent normalization of plasma phytanic acid levels may also be observed in IRD patients, possibly depending on their diet (Poll-The et al. 2004) , its value as a biochemical diagnostic parameter may be less reliable, prompting the need to combine it with other biochemical diagnostic parameters.
The missense variant c.2528G>A (p.Gly843Asp) in PEX1 is the most commonly found pathogenic mutation in different patient cohorts (25-40% of the ZSD patients) (Ebberink et al. 2011) and is associated with a mild phenotype, meaning that IRD patients may live several decades (Crane et al. 2005) . Accordingly, an earlier diagnosis will enable a more effective intervention in these patients. Systematic evaluation of long-term biochemical, clinical and developmental effects of a low phytanic acid intake diet in IRD patients may prove whether this could be a useful supplement to the recommended management of this disorder.
Synopsis
In spite of being a peroxisomal biogenesis disorder, infantile Refsum disease may have residual peroxisomal activity once we obtained a decrease of phytanic acid plasma levels, along with a low phytanic acid diet, in a 3-year-old child with the common pathogenic p.(Gly843Asp) mutation in the PEX1 gene.
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